Type of treatment escalation in the FL-IFX treatment group within 52 weeks
| Number of patients needing treatment escalation in the FL-IFX group, per-treatment escalation type | |
| Continuation of IFX after five infusions; n (%) | 12/49 (24.5) |
| Restart anti-TNF therapy; n (%) | 7/49 (14.5) |
| Infliximab; n | 6 |
| Adalimumab; n | 1 |
| Corticosteroid course; n (%) | 2/49 (4) |
FL-IFX, first-line infliximab; TNF, tumour necrosis factor.